Perrigo Company plc

PRGO ·Healthcare, Drug Manufacturers - General, Ireland
Financial Statements › Cash Flow Statement
Annual Quarterly

Cash Flow Statement

Line Item FY2025 FY2024 FY2023 FY2022 FY2021 FY2020 FY2019 FY2018
Operating Activities
Net Income $-1.43B $-171.8M $-12.7M $-140.6M $-68.9M $-162.6M $146.1M $131.0M
Depreciation & Amortization $337.5M $325.9M $359.5M $338.6M $312.2M $384.8M $396.5M $423.6M
Depreciation $114.8M $97.4M $93.7M $86.2M $86.8M $75.6M $77.5M $90.0M
Amortization $222.7M $228.5M $265.8M $252.4M $210.0M $212.2M $219.6M $333.6M
Stock-Based Compensation $54.6M $64.4M $68.8M $54.9M $60.1M $58.5M $52.2M $37.7M
Net Cash from Operating Activities $238.5M $362.9M $405.5M $307.3M $156.3M $636.2M $387.8M $593.0M
Investing Activities
Capital Expenditures $93.4M $118.3M $101.7M $96.4M $152.1M $170.4M $137.7M $102.6M
Business Acquisitions — $0 $0 $2.01B $0 $168.5M $747.7M $0
Net Cash from Investing Activities $-75.4M $78.8M $-77.5M $-1.96B $1.28B $-187.8M $-596.1M $-126.8M
Financing Activities
Dividends Paid $159.3M $152.5M $149.7M $142.4M $129.6M $123.9M $112.4M $104.9M
Stock Repurchases — — — $0 $0 $164.2M $0 $400.0M
Net Cash from Financing Activities $-220.5M $-611.0M $-187.2M $421.6M $-178.7M $-181.1M $1.8M $-571.9M
Net Change in Cash $-24.9M $-192.5M $150.6M $-1.28B $1.24B $287.2M $-196.8M $-127.6M
Free Cash Flow $145.1M $244.6M $303.8M $210.9M $4.2M $465.8M $250.1M $490.4M
← Newer Page 1 of 2 Older →